Vaxil Bio Ownership
| VXL Stock | CAD 0.21 0.01 4.55% |
Shares in Circulation | First Issued 2009-09-30 | Previous Quarter 137 M | Current Value 137 M | Avarage Shares Outstanding 56.5 M | Quarterly Volatility 55.2 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Vaxil |
Vaxil Stock Ownership Analysis
The company has Price to Book (P/B) ratio of 0.89. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Vaxil Bio recorded a loss per share of 0.06. The entity had not issued any dividends in recent years. The firm had 1:50 split on the 15th of May 2025. Vaxil Bio Ltd., an immunotherapy biotech company, engages in the research and development of immunotherapies for cancer and infectious diseases in Israel. The company was founded in 2006 and is headquartered in Toronto, Canada. VAXIL BIO is traded on TSX Venture Exchange in Canada. For more information please call Yuval Avnir at 647-558-5564 or visit https://vaxil-bio.com.Vaxil Bio Outstanding Bonds
Vaxil Bio issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Vaxil Bio uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Vaxil bonds can be classified according to their maturity, which is the date when Vaxil Bio has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Vaxil Stock Analysis
When running Vaxil Bio's price analysis, check to measure Vaxil Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxil Bio is operating at the current time. Most of Vaxil Bio's value examination focuses on studying past and present price action to predict the probability of Vaxil Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxil Bio's price. Additionally, you may evaluate how the addition of Vaxil Bio to your portfolios can decrease your overall portfolio volatility.